References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.

[2] Dai CM, Jin S, Zhang JZ. Effect of Dahuang Zhechong Pills combined with TACE on VEGF, MMP-2, TGF-β1 and immune function of patients with primary liver cancer (blood stasis and collaterals blocking type) [J]. China J Chin Mater Med, 2021, 46(3): 722-729.

[3] Cheng J, Zhao Q, Zhou Y, Tang L, Sheraz M, Chang J, Guo JT. Interferon Alpha Induces Multiple Cellular Proteins That Coordinately Suppress Hepadnaviral Covalently Closed Circular DNA Transcription. J Virol., 2020 Aug 17; 94(17):e00442-20.

[4] Seeger C. Control of viral transcripts as a concept for future HBV therapies [J]. CurrOpin Virol, 2018, 30: 18-23.

[5] LI Yimin, Yuan Lin, Yang Shengyong, et al. ADAR1 expression pattern and HBV replication inhibition in hepatocellular carcinoma cells induced by interferon [J]. Journal of the Third Military Medical University, 2019, 41(14):1336-1342.

[6] Dubrot J, Du PP, Lane-Reticker SK. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat Immunol,  2022 Oct; 23 (10): 1495-1506.

[7] Li Jie, Yan Kun, Yang Yi et al. Interleukin-17 promotes the growth and proliferation of mouse hepatocellular carcinoma cells by antagonizing γ- interferon [J]. Journal of Southern Medical University, 2019, 39(01):1-5.

[8] Lan Y R, Sun P, Duan X G, et al. Regulation of interferon alpha on Tfh cell differentiation in mice [J]. Advances in Veterinary Medicine, 2019, 41(2):18-22. (in Chinese)

[9] Wang M, Fan W H, Li C et al. Research progress of avian interferon in immune response [J]. Chinese Journal of Animal Infectious Diseases, 2019, 30(01):211-218. (in Chinese)

[10] Li M, Zhang L, Lu Y, et al. Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonalpha-2a [J]. Virol Sin, 2021, 36(2): 311-320.

[11] Li Y, He M, Gong R, Wang Z, Lu L, Peng S, Duan Z, Feng Y, Liu Y, Gao B. Forkhead O transcription factor 4 restricts HBV covalently closed circular DNA transcription and HBV replication through genetic downregulation of hepatocyte nuclear factor 4 alpha and epigenetic suppression of covalently closed circular DNA via interacting with promyelocytic leukemia protein. J Virol, 2022 Jul 13; 96(13):e0054622.

[12] Luo H, Hu X, Li Y, Lei D, Tan G, Zeng Y, Qin B. The antiviral activity of tripartite motif protein 38 in hepatitis B virus replica-tion and gene expression and its association with treatment responses during PEG-IFN- α antiviral therapy. Virol, 2023 Feb; 579:84-93.

[13] Choi H S J, van Campenhout M J H, van Vuuren A J, et al. Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection [J]. Clin Gastroenterol Hepatol, 2021, 19(9): 1933-40 e1.

[14] Lin Y J, Sun F F, Zeng Z, et al. Combination and intermittent therapy based on pegylated interferon alfa-2a for chronic hepatitis B with nucleoside (nucleotide) analog-experienced resulting in hepatitis B surface antigen clearance: a case report [J]. Viral Immunol, 2022, 35(1):71-75.

[15] Wang H, Li Yan-Chun, Gao Qiu-Ying, et al. Effect of imatinib combined with recombinant human interferon α-2b on serum MMP-2, SALL4 mRNA and AGP levels in patients with accelerated chronic myeloid leukemia [J]. Chinese Journal of Clinical Oncology, 2019, 16(05):468-473.

[16] Liu Q, Rong G, Li Wei, Hu Jianwei, et al. Effect of Ralidomide combined with interferon-alpha on proliferation of multiple mye-loma U266 cells [J]. Chinese Journal of Chronic Disease Prevention and Control, 2019, 27(02):133-136.

[17] Zhou J, Zhang W F. PEG-IFN- α-2A combined with ADV treatment for hepatitis B with high viral load e antigen positive [J]. Journal of Hebei Medicine, 2019, 27(08):1394-1399.

[18] Zhang C Y. Meta-analysis of efficacy and safety of interferon alpha combined with thymosin α1 in the treatment of chronic hepatitis B [D]. Shihezi University, 2018.

[19] Qi Wenqian, Wang Jiangbin, Zhang Q, et al. Early combination therapy of pegylated interferon and nucleoside (acid) analogues can effectively improve the antiviral efficacy and long-term prognosis of HBV DNA-positive primary liver cancer patients after hepatectomy/ablation [J]. Journal of Clinical Hepatobiliary Diseases, 2019, 36(06):1355.

[20] Zhang C F. A retrospective study of chronic hepatitis B treated with pegylated interferon combined with traditional Chinese medicine for 2 years [D]. Shanghai University of Traditional Chinese Medicine, 2023.

[21] Weng DD, Chen L D, Xu X, et al. Efficacy and safety evaluation of nucleoside (acid) drugs combined with interferon in the treatment of patients with low level of hepatitis B surface antigen [J]. Modern Practical Medicine, 2019, 35(01):112-115.

[22] Hu, B., Yu, M., Ma, X., et al. IFN-alpha Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment. Cancer Discovery, 2022, 12, 1718-1741.

[23] Jin J. Effect analysis of Entecavir and interferon sequential therapy for chronic hepatitis B with high viral load [J]. Current Medicine, 2018, 24(26):64- 66. (in Chinese)

[24] Zhu SHS, Dong Yi, Zhang Hongfei, et al. Effect of randomized controlled interferon sequential combined with lamivudine antiviral therapy on immune tolerance in children with chronic hepatitis B [J]. Chinese Journal of Hepatology, 2019, 27(8):604-609.